BiotechTube
Home/Mesoblast/John J. Smith
JJ

John J. Smith

Chief Financial Officer

Mesoblast

Therapeutic Areas

Hematology/OncologyCardiovascularOrthopedicImmunology

Mesoblast Pipeline

DrugIndicationPhase
RYONCIL (remestemcel-L)Pediatric Steroid-Refractory Acute Graft-Versus-Host DiseaseApproved
REVASCOR (rexlemestrocel-L)Advanced Chronic Heart Failure (HFrEF)Phase 3
MPC-06-IDChronic Low Back Pain due to Degenerative Disc DiseasePhase 3
Remestemcel-LAcute Respiratory Distress Syndrome (ARDS)Phase 3

Leadership Team at Mesoblast

DS
Dr. Silviu Itescu
Founder & Chief Executive Officer
DF
Dr. Fred Grossman
Chief Medical Officer
JM
Joshua Muntner
Chief Commercial Officer (U.S.)
DD
Dr. Donna Skerrett
Chief Medical Officer (U.S.)
PS
Professor Sir Graham L. Patrick
Board Director
DJ
Dr. John J. L. Ho
Board Director
View full Mesoblast profile